Synthesis of radio-and stable-labelled LAF237(Galvus, Vildagliptin)CISZEWSKA, Grazyna; ALLENTOFF, Alban; JONES, Lawrence et al.Journal of labelled compounds & radiopharmaceuticals. 2007, Vol 50, Num 5-6, pp 593-594, issn 0362-4803, 2 p.Conference Paper

DPP-4 inhibitors and their potential role in the management of type 2 diabetesBARNETT, A.International journal of clinical practice (Esher). 2006, Vol 60, Num 11, pp 1454-1470, issn 1368-5031, 17 p.Article

GLP-1 based therapy for type 2 diabetesARULMOZHI, D. K; PORTHA, B.European journal of pharmaceutical sciences. 2006, Vol 28, Num 1-2, pp 96-108, issn 0928-0987, 13 p.Article

DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumptionPIPATPIBOON, Noppamas; PINTANA, Hiranya; PRATCHAYASAKUL, Wasana et al.European journal of neuroscience (Print). 2013, Vol 37, Num 5-6, pp 839-849, issn 0953-816X, 11 p.Article

The role of vildagliptin in the management of type 2 diabetes mellitusKLAPPINGER, Erika L; HALMA, K.The Annals of pharmacotherapy. 2007, Vol 41, Num 5, pp 824-832, issn 1060-0280, 9 p.Article

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteersHE, Yan-Ling; SADLER, Brian M; SABO, Ron et al.Clinical pharmacokinetics. 2007, Vol 46, Num 9, pp 787-802, issn 0312-5963, 16 p.Article

Clinical Pharmacokinetics and Pharmacodynamics of VildagliptinHE, Yan-Ling.Clinical pharmacokinetics. 2012, Vol 51, Num 3, pp 147-162, issn 0312-5963, 16 p.Article

Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IVLANDERSDORFER, Cornelia B; HE, Yan-Ling; JUSKO, William J et al.British journal of clinical pharmacology. 2012, Vol 73, Num 3, pp 391-401, issn 0306-5251, 11 p.Article

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteersHE, Yan-Ling; SABO, Ron; CAMPESTRINI, Joelle et al.British journal of clinical pharmacology. 2008, Vol 65, Num 3, pp 338-346, issn 0306-5251, 9 p.Article

Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metforminFORST, Thomas; BRAMLAGE, Peter.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 9, pp 1299-1313, issn 1465-6566, 15 p.Article

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-AnalysisPARK, Haesuk; PARK, Chanhyun; KIM, Yoona et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1453-1469, issn 1060-0280, 17 p.Article

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes MellitusNEUMILLER, Joshua J; WOOD, Lindy; CAMPBELL, R. Keith et al.Pharmacotherapy. 2010, Vol 30, Num 5, pp 463-484, issn 0277-0008, 22 p.Article

Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitusLANGLEY, Alissa K; SUFFOLETTA, Terri J; JENNINGS, Heath R et al.Pharmacotherapy. 2007, Vol 27, Num 8, pp 1163-1180, issn 0277-0008, 18 p.Article

Prise en charge d'un diabète insulinotraité Intérêt des IDPP4COSSON, Emmanuel.Diabète & obésité. 2013, Vol 8, Num 70, pp 178-181, issn 1957-5238, 4 p.Article

Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic ratsMAEDA, Sayaka; MATSUI, Takanori; YAMAGISHI, Sho-Ichi et al.International journal of cardiology. 2012, Vol 158, Num 1, pp 171-173, issn 0167-5273, 3 p.Article

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trialsCAI, L; CAIT, Y; LU, Z. J et al.Journal of clinical pharmacy and therapeutics (Print). 2012, Vol 37, Num 4, pp 386-398, issn 0269-4727, 13 p.Article

Inhibiteurs de la dipeptidyl-peptidase-4: place thérapeutique actuelle, perspectives et questions non résoluesBLICKLE, Jean-Frédéric.MT. Médecine thérapeutique. 2010, Vol 16, Num 2, pp 105-114, issn 1264-6520, 10 p.Article

Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairmentHE, Yan-Ling; KULMATYCKI, Kenneth; YIMING ZHANG et al.International journal of clinical pharmacology and therapeutics. 2013, Vol 51, Num 9, pp 693-703, issn 0946-1965, 11 p.Article

Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesusVEDTOFTE, Louise; BODVARSDOTTIR, Thora B; GOTFREDSEN, Carsten F et al.Regulatory peptides. 2010, Vol 160, Num 1-3, pp 106-114, issn 0167-0115, 9 p.Article

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptinHE, Y.-L; SABO, R; CAMPESTRINI, J et al.European journal of clinical pharmacology. 2007, Vol 63, Num 7, pp 677-686, issn 0031-6970, 10 p.Article

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A ReviewRICHARD, Kathleen R; SHELBURNE, Jamie S; KIRK, Julienne K et al.Clinical therapeutics. 2011, Vol 33, Num 11, pp 1609-1629, issn 0149-2918, 21 p.Article

Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetesHE, Yan-Ling; VALENCIA, Jessica; YIMING ZHANG et al.British journal of clinical pharmacology. 2010, Vol 70, Num 1, pp 34-42, issn 0306-5251, 9 p.Article

Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabète de type 2 = Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetesSCHEEN, A. J.RMLG. Revue médicale de Liège. 2007, Vol 62, Num 4, pp 217-221, issn 0370-629X, 5 p.Article

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminBOSI, Emanuele; CAMISASCA, Riccardo Paolo; COLLOBER, Carole et al.Diabetes care. 2007, Vol 30, Num 4, pp 890-895, issn 0149-5992, 6 p.Article

VildagliptinHENNESS, Sheridan; KEAM, Susan J; EVANS, Marc et al.Drugs (Basel). 2006, Vol 66, Num 15, pp 1989-2004, issn 0012-6667, 16 p.Article